ArticlePloS one2026
Association of IL-6 and IL-10 serum levels with genetic variants in diabetic neuropathy: Clinical findings from a Bangladeshi patient cohort.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetic Neuropathy (DN) is a prevalent complication of diabetes linked to chronic inflammation. Interleukin-6 (IL-6) and Interleukin-10 (IL-10) are key cytokines implicated in DN pathogenesis. This study investigates the association of IL6 and IL10 gene polymorphisms and serum levels with DN in the Bangladeshi population. MATERIALS AND
methodsA case-control study was conducted with 225 participants: diabetic patients with DN (n = 75), diabetic patients without DN (n = 75), and healthy controls (n = 75). Genomic DNA was extracted for genotyping IL-6 (rs1800796) and IL-10 (rs1800896) SNPs via PCR. Serum cytokine levels were measured using ELISA.
resultsSerum IL-6 levels were significantly higher in the DN group than in the other study groups (p < 0.0001), with the highest levels observed among individuals with the IL-6 rs1800796 CC genotype. In unadjusted analyses, the IL-6 CC genotype was associated with increased odds of DN compared with healthy controls (OR = 4.813, 95% CI: 1.752-13.85, p = 0.0040), as was the IL-10 GG genotype (OR = 2.679, 95% CI: 1.000-6.751, p = 0.0373). However, neither IL-6 nor IL-10 genotype remained independently associated with DN after multivariable adjustment. Serum IL-10 levels did not differ significantly among the study groups (p = 0.0948). Combined genotype analyses showed several nominal associations, although these findings were exploratory. Serum IL-6 showed promising discriminatory ability in distinguishing patients with DN from the other study groups, whereas IL-10 demonstrated limited discriminatory performance.
conclusionThese findings support further investigation of serum IL-6 as a potential candidate biomarker for diabetic neuropathy, whereas the independent contribution of the investigated IL-6 and IL-10 polymorphisms remains uncertain. Larger prospective studies with independent external validation are required before clinical application can be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.